Roche Diagnostics evaluates new biomarker opportunities by continuously monitoring universities, start-ups, medical and research institutes, mid sized and large companies.

The goal is to identify biomarkers that address significant unmet medical needs to enable novel and important physician decision making along the entire continuum of a patient’s journey.

Roche’s tests provide crucial knowledge about the different diseases during the whole spectrum of care (screening - diagnosis - prognosis - prediction - monitoring), enabling physicians and caretakers to intervene early and to actively manage patients’ health conditions.

  • Oncology

  • Cardiovascular diseases

  • Infectious diseases

  • Central nervous system diseases, including brain traumatism

  • Women's health

  • Respiratory diseases

  • Coagulation and haematology

  • Autoimmune diseases and inflammation

  • Diabetes and other metabolic diseases

The biomarker-driven drug development across the industry is driving the group's personalised healthcare strategy across many therapeutic areas for different intended uses.

If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

you go to an external page